MiniMed Group, Inc. (MMED) intrinsic value & 10-year financials
MiniMed Group, Inc. (MMED) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 4 fiscal years revenue grew 12.1% a year to $3.1B, with an average return on invested capital of -5.0%.
- Graham intrinsic value
- —
- Revenue (FY2026)
- $3.1B
- Revenue growth (4-yr CAGR)
- 12.1%
- ROIC (10-yr avg)
- -5.0%
- Free cash flow (FY2026)
- -$420.0M
MMED 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2026 | $3.1B | -$333.0M | -$1.30 | -$420.0M | -6.1% | -5.6% |
| FY2025 | $2.7B | -$213.0M | -$0.84 | -$53.0M | -5.4% | -4.3% |
| FY2024 | $2.5B | -$112.0M | -$0.44 | -$107.0M | -2.8% | — |
| FY2023 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
MiniMed Group, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
MiniMed Group, Inc. has historically struggled to out-earn its cost of capital, averaging just -5.0% ROIC.
MiniMed Group, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, MiniMed Group, Inc. is modeled at 12.1% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-36.65 per share.